Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy

Updated phase I results with extended follow-up show antitumor activity of patritumab deruxtecan in patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC across various EGFR TKI resistance mechanisms and regardless of prior therapy or presence of CNS metastases.